WELCOME to Neurodyn
Neurodyn Inc. is a Canadian biotechnology company utilizing a portfolio approach to identify, validate and develop bioactives for the early treatment of neurological diseases. Neurodyn's business model is to maintain a dynamic portfolio of drug candidates focusing on joint ventures, out-licensing and partnering once each drug candidate that moves through the pipeline has reached a value-inflection point.
1) international partners with demonstrated historical knowledge of natural health products,
2) in-house medicinal chemistry capability, and
3) proprietary animal models of neurological disease.
This combination of expertise provides Neurodyn with a unique insight into the discovery, validation and development of new compounds for the treatment of neurological diseases, and actively partners with industry at all stages of the lead compound discovery and the value-added process of drug development.
NeuroQuest Inc. (neuroquest.ca), a wholly-owned subsidiary, conducts synthesis and medicinal chemistry programs for the molecular modification of promising BioActive compounds.
CNS CRO (cnscro.com), a second wholly-owned contract research subsidiary of Neurodyn, offers specialty neurological Contract Research Services in ALS, Parkinson's disease, Alzheimer's disease, epilepsy, schizophrenia, stroke and cognitive function testing.
TECHNOLOGY Overview
A robust product pipeline has developed from the BioActives Discovery Engine™, including:
ND-1004
Neurodyn Inc. (neurodyn.ca) is a Canadian biotechnology company which identifies, validates and develops natural BioActives for the early treatment of neurological diseases. Neurodyn is conducting a natural product drug development program with a botanical extract that shows compelling evidence for protection of early stage Parkinson’s disease (PD). PD is the second-most more
NQ-1065
Neurodyn Inc. (neurodyn.ca) is a Canadian biotechnology company which identifies, validates and develops natural BioActives for the early treatment of neurological diseases. Neurodyn is conducting a drug development program with first-in-class neuromodulators, with promising lead compounds being characterized in preparation for an IND. This research is being conducted by NeuroQuest Inc... more